UP!

COO $333.24   View long term graphs

The Cooper Companies, Inc.
Type
Public
Traded as NYSE: COO
S&P 500 Component
Industry Medical Devices
Predecessor Martin H. Smith Co., Cooper Tinsley Laboratories, Inc.
Founded 1958 (1958)
Founder Martin H. Smith Co
Headquarters Pleasanton, California
Area served
Worldwide
Key people
Robert S. Weiss, CEO & Director
Products Contact lenses, medical products and equipment for treating women
Revenue Increase US$1331 million (2011)
Operating income
Increase US$228 million (2011)
Net income
Increase US$175 million (2011)
Total assets Increase US$2625 million (2011)
Total equity Increase US$1937 million (2011)
Number of employees
Increase 7400 (2011)
Divisions CooperVision (CVI), CooperSurgical (CSI)
Website www.coopercos.com

The Cooper Companies, Inc. is a US based, multinational company in the medical specialities sector. With its headquarters in Pleasanton, California, it has over 8,000 employees and consists of two subsidiaries, CooperVision (CVI) that provides contact lenses for both wearers and practitioners, and CooperSurgical (CSI) that provides products for health care professionals and establishments that are involved in women’s health care. Contact lens sales, in particular, soft toric lenses which correct astigmatism, make up for 80% of Cooper Company sales. Cooper Companies has manufacturing facilities in the UK, Puerto Rico and New York and distributes from Rochester, NY, Fareham, UK and Liege, Belgium, among many other smaller distribution locations.

Founded in 1958 by predecessor, Martin H. Smith Co, and then incorporated as Cooper Tinsley Laboratories, Inc. in 1961, the company changed its name to Cooper Laboratories Inc. in 1967. In 1979 Cooper Laboratories introduced their first soft contact lens in the United States. During a re-structuring in the 1980s, Cooper Laboratories was re-organised into three groups, CooperVision, CooperCare and CooperBiomedical, with a further group, Cooper Medical Devices Corp, added a year later. In 1987 the company adopted the name of Cooper Companies, with CooperVision existing as a subsidiary. By the 1990s, through various acquisitions and expansions, the company had expanded into other areas of healthcare, including, among others, medical devices and ophthalmic pharmaceuticals.

The President and Chief Executive Officer & Director is Robert S. Weiss'.

Mutual fund holders 62.21% Other institutional 34.90% Individual stakeholders 1.13%

2011 – Contact lenses from the Avaira line were recalled following an investigation by the United States Food and Drug Administration into claims that the level of silicone oil residue on the contact lenses could cause blurred vision and discomfort.

In 2012 Cooper Companies, Inc settled $27.0 million on a claim brought by a group of stockholders after claims that Cooper Companies misled them about the problems they were facing with contact lenses produced overseas, contact lenses that were subsequently recalled.

In 1988, Cooper Companies was involved in a case brought against them by Medical Engineering Corp, part of the Bristol-Myers Squibb Company, after they claimed that Cooper Companies had agreed to assume responsibility for breast implants that were manufactured while they still owned the business. This was one of many lawsuits related to breast implants and the issue was resolved in 1993 when Medical Engineering agreed to pay all legal costs relating to breast implants, both in the future and still in dispute.

CooperSurgical:

CooperVision:

Through its subsidiary, CooperVision, Cooper Companies is involved in various schemes and scholarship programmes in the UK, including the Park Sport initiative, a scheme run by Eastleigh Borough Council that offers different sporting activities to local families for free. It also hosts a Student Research Scholarship which encourages optometry students to take part in contact lens-based research projects.

News

The Cooper Companies, Inc. 1.28% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2020-12-03 Future report Set alerts
Q3 2020 2020-09-03 2.28 1.12
Q2 2020 2020-06-04 1.51 0.23
Q1 2020 2020-03-05 2.69 1.82
Q4 2019 2019-12-05 3.30 2.42
Q3 2019 2019-08-29 3.23 2.40
Q2 2019 2019-05-30 2.94 2.45
Q1 2019 2019-03-05 2.88 2.07
Q4 2018 2018-12-06 2.87 2.02
Q3 2018 2018-08-30 3.00 2.03

Ratings

2016-06-30 Boost Price Target Stifel Nicolaus Buy $180.00 to $195.00
2016-06-25 Reiterated Rating Robert W. Baird Outperform $185.00
2016-06-04 Reiterated Rating Stephens Hold
2016-06-04 Reiterated Rating Piper Jaffray Buy
2016-06-04 Reiterated Rating Piper Jaffray Cos. Buy
2016-06-03 Reiterated Rating Wells Fargo Hold
2016-06-03 Reiterated Rating Wells Fargo & Co. Hold
2016-06-02 Reiterated Rating Jefferies Group Buy $175.00 to $190.00
2016-05-16 Upgrade Cleveland Research Neutral to Buy
2016-04-19 Reiterated Rating Robert W. Baird Buy
2016-04-15 Upgrade Jefferies Group Hold to Buy $175.00
2016-03-05 Reiterated Rating Stephens Hold
2015-12-17 Initiated Coverage Goldman Sachs Neutral $143.00
2015-12-17 Initiated Coverage Goldman Sachs Group Inc. Neutral $143.00
2015-12-07 Reiterated Rating Stifel Nicolaus Buy
2015-12-05 Reiterated Rating Piper Jaffray Buy
2015-12-04 Lower Price Target Robert W. Baird Outperform $171.00 to $155.00
2015-12-04 Lower Price Target Raymond James Outperform $168.00 to $155.00
2015-12-04 Lower Price Target KeyBanc Overweight $200.00 to $168.00
2015-12-04 Lower Price Target Jefferies Group Hold $170.00 to $136.00
2015-12-04 Lower Price Target BMO Capital Markets $180.00 to $150.00
2015-12-04 Reiterated Rating Piper Jaffray Overweight $205.00 to $145.00
2015-12-04 Downgrade JPMorgan Chase & Co. Overweight to Neutral $175.00 to $145.00
2015-12-04 Lower Price Target Raymond James Financial Inc. Outperform $168.00 to $155.00
2015-12-04 Lower Price Target KeyCorp Overweight $200.00 to $168.00
2015-12-01 Lower Price Target Stifel Nicolaus Buy $200.00 to $180.00
2015-11-23 Reiterated Rating Piper Jaffray Buy $212.50 to $205.00
2015-11-17 Downgrade Wells Fargo Outperform to Market Perform
2015-10-09 Lower Price Target Robert W. Baird Market Outperform $195.00 to $171.00
2015-10-09 Lower Price Target BMO Capital Markets $196.00 to $180.00
2015-09-04 Lower Price Target Raymond James $200.00 to $175.00
2015-09-04 Reiterated Rating William Blair Outperform
2015-09-04 Reiterated Rating BMO Capital Markets Outperform $204.00 to $196.00
2015-09-04 Reiterated Rating Piper Jaffray Buy $212.50
2015-08-27 Reiterated Rating Piper Jaffray Overweight $212.50
2015-08-26 Upgrade KeyBanc Sector Weight to Overweight $200.00
2015-06-06 Reiterated Rating Piper Jaffray Overweight $212.50
2015-06-05 Boost Price Target Oppenheimer Market Perform $178.00 to $182.00
2015-06-05 Boost Price Target Oppenheimer Holdings Inc. Market Perform $178.00 to $182.00
2015-03-31 Boost Price Target BMO Capital Markets Outperform $180.00 to $209.00
2015-03-25 Boost Price Target JPMorgan Chase & Co. Overweight $195.00 to $210.00
2015-03-19 Initiated Coverage Piper Jaffray Overweight $212.50
2015-03-06 Boost Price Target BMO Capital Markets Outperform $177.00 to $180.00
2015-03-06 Boost Price Target Oppenheimer Market Perform $170.00 to $178.00
2014-12-15 Initiated Coverage Oppenheimer Market Perform $170.00
2014-10-14 Reiterated Rating JPMorgan Chase & Co. Neutral $37.00 to $36.00
2014-09-12 Reiterated Rating JPMorgan Chase & Co. Overweight $180.00 to $195.00
2014-09-08 Reiterated Rating Jefferies Group Hold $135.00 to $170.00
2014-08-28 Boost Price Target Raymond James Outperform $160.00 to $175.00
2014-08-15 Reiterated Stifel Buy $150 to $180
2014-08-15 Boost Price Target Stifel Nicolaus Buy $150.00 to $180.00
2014-07-01 Reiterated Rating JPMorgan Chase & Co. Overweight $176.00 to $150.00
2014-06-06 Reiterated Rating JPMorgan Chase & Co. Overweight $140.00 to $150.00
2014-04-09 Initiated Coverage KeyBanc Hold
2014-02-03 Downgrade Cleveland Research Buy to Neutral
2014-01-07 Downgrade Citigroup Inc. Neutral to Sell $128.00 to $116.00
2013-12-06 Reiterated Rating Citigroup Inc. Neutral $133.00 to $128.00
2011-09-30 Reiterated Morgan Keegan Outperform $85 to $95
2011-08-11 Initiated William Blair Outperform
2009-11-18 Initiated Morgan Keegan Outperform
2009-03-04 Reiterated Jefferies & Co Hold $16 to $20
2008-05-12 Initiated Citigroup Buy
2008-03-07 Reiterated BMO Capital Markets Market Perform $44 to $40
2008-02-14 Downgrade FTN Midwest Buy to Neutral
2007-12-12 Reiterated Jefferies & Co Hold $46 to $41
2007-10-09 Downgrade JP Morgan Neutral to Underweight
2007-10-04 Downgrade Bear Stearns Peer Perform to Underperform
2007-09-07 Upgrade Citigroup Hold to Buy
2007-08-23 Initiated Jefferies & Co Hold $48
2007-07-11 Initiated Wachovia Mkt Perform
2007-05-21 Upgrade FTN Midwest Neutral to Buy
2007-03-30 Reiterated Goldman Sachs Buy $54 to $56
2007-03-09 Reiterated Piper Jaffray Market Perform $47 to $51
2007-02-01 Upgrade Bear Stearns Underperform to Peer Perform $47.70
2016-06-30 Boost Price Target Stifel Nicolaus Buy $180.00 to $195.00
2016-06-25 Reiterated Rating Robert W. Baird Outperform $185.00
2016-06-04 Reiterated Rating Stephens Hold
2016-06-04 Reiterated Rating Piper Jaffray Buy
2016-06-04 Reiterated Rating Piper Jaffray Cos. Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
WEISS ROBERT S President and CEO 0.21%  (99167) ARAY / COO /
KAUFMAN CAROL R Secretary, EVP, & CAO 0.10%  (45898) CHDX / COO / NSP /
PRESS DONALD 0.09%  (43970) COO /
White Albert G III VP Investor Rel., Treas. & CSO 0.08%  (37874) COO /
McBride Daniel G VP, General Counsel & CRO 0.06%  (30542) COO /
WEBER JOHN ARTHUR President, CooperVision, Inc. 0.03%  (15260) COO /
Matz Gregory W VP & CFO 0.03%  (15123) COO /
ROSENBERG STEVEN 0.03%  (12359) BERK / COO /
Lindell Jody S 0.02%  (11403) COO / PDLI /
BENDER A THOMAS 0.02%  (11205) COO /
PICHOTTA NICHOLAS J Pres, CEO Cooper Medical, Inc. 0.02%  (10697) COO /
ZINBERG STANLEY MD 0.02%  (9879) COO /
FOLDEN RODNEY VP & Corporate Controller 0.02%  (8592) COO /
KALKSTEIN MICHAEL 0.02%  (8320) COO /
RUBENSTEIN ALLAN E 0.01%  (5568) COO /
Golden Randal General Counsel 0.01%  (2885) COO /
Maloney Tina Corporate Controller 0.01%  (2874) AMRS / COO /
Andrews Brian G Treasurer 0.01%  (2642) COO /
Ricupati Agostino Sr. VP, Finance & Tax 0.01%  (2428) COO /

Comments